{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T20:51:44Z","timestamp":1774299104382,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejpn.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:02:04Z","timestamp":1772524924000},"page":"A4-A6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CLN2 disease: why early diagnosis matters more than ever"],"prefix":"10.1016","volume":"60","author":[{"given":"Pasquale","family":"Striano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2026.03.001_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejpn.2025.12.001","article-title":"Incidence and timing of diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2): a nationwide study using the French hospital discharge database","volume":"60","author":"Auvin","year":"2026","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ejpn.2026.03.001_bib2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14737175.2021.1885374","article-title":"Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies","volume":"21","author":"Mazurkiewicz-Be\u0142dzi\u0144ska","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejpn.2026.03.001_bib3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","article-title":"Disease characteristics and progression in patients with late infantile neuronal ceroid lipofuscinosis type 2 disease: an observational cohort study","volume":"2","author":"Nickel","year":"2018","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.ejpn.2026.03.001_bib4","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpn.2026.03.001_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(23)00384-8","article-title":"Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 disease: an open label extension study","volume":"23","author":"Schulz","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2026.03.001_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13023-021-01858-6","article-title":"Presymptomatic treatment of classic late infantile neuronal ceroid lipofuscinosis with cerliponase alfa","volume":"16","author":"Schaefers","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejpn.2026.03.001_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","article-title":"Management strategies for CLN2 disease","volume":"69","author":"Williams","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ejpn.2026.03.001_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ymgme.2016.07.011","article-title":"Diagnosis of neuronal ceroid lipofuscinosis type 2 disease: expert recommendations for early detection and laboratory diagnosis","volume":"119","author":"Fietz","year":"2016","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejpn.2026.03.001_bib9","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/B978-0-444-59565-2.00038-1","article-title":"Neuronal ceroid lipofuscinoses","volume":"113","author":"Mole","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ejpn.2026.03.001_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.gene.2016.08.031","article-title":"Analysis of large scale whole exome sequencing data to determine the prevalence of genetically distinct forms of neuronal ceroid lipofuscinosis","volume":"593","author":"Sleat","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.ejpn.2026.03.001_bib11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/s-0043-1770143","article-title":"Language delay in patients with CLN2 disease: could it support earlier diagnosis","volume":"54","author":"Nickel","year":"2023","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ejpn.2026.03.001_bib12","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/jpc.14890","article-title":"Neuronal ceroid lipofuscinosis type 2: an Australian case series","volume":"56","author":"Johnson","year":"2020","journal-title":"J. Paediatr. Child Health"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379826000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379826000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T20:00:03Z","timestamp":1774296003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379826000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":12,"alternative-id":["S1090379826000103"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2026.03.001","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CLN2 disease: why early diagnosis matters more than ever","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}